This trial is evaluating whether Magnetic Resonance Spectroscopic Imaging will improve 1 primary outcome and 6 secondary outcomes in patients with Brain Cancer. Measurement will happen over the course of Up to 1 year.
This trial requires 13 total participants across 2 different treatment groups
This trial involves 2 different treatments. Magnetic Resonance Spectroscopic Imaging is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are in Phase 1 and are in the first stage of evaluation with people.
Approximately 18,000 new cases of primary [brain cancer](https://www.withpower.com/clinical-trials/brain-cancer) are diagnosed each year in the United States, making it the most common cancer of the central nervous system. More than 7,500 Americans die every year of a primary brain cancer. Older people have lower survival rates from primary brain cancer.
The majority of the general public are not at all familiar with the disease. The diagnosis, the treatment and its complications are not well understood by the public. A mass campaign to educate the public on the disease is highly advisable to promote early stage diagnosis and improved management. In addition to raising public awareness, it would be prudent to develop an information web portal for patients presenting with brain tumor to a general practitioner or other specialist. To ensure a prompt diagnosis, we recommend that, at the time of presentation to a specialist clinic, if there are two neurologists available, they should be advised of the possibility of an intracranial haemangiopericytoma or a neuroendocrine tumour.
There are many different treatments available for [brain cancer](https://www.withpower.com/clinical-trials/brain-cancer). There are two main types of treatments administered: surgery and radiation therapy. The types of surgery used are debulking surgery for glioblastoma multiforme, proton therapy to treat primary brain metastases, and other types of surgery for specific types of brain cancer. The types of radiation treatments used are external beam radiation therapy to treat primary brain cancer, and stereotactic radiation therapy for the treatment of brain tumors. Both surgery and radiation therapy may be used in combination.
The most popular theory is that schizophrenia increases the risk of developing brain cancer. This is not supported by many large studies. The evidence for other causes includes genetics predisposing to brain cancer, and a link to the use of neuroleptics in schizophrenia and dementia. A link between brain malignancy and depression is also suggested. There is no one cause, but the disease is most likely multiple and diverse.
This data provides an example of an ethical dilemma in the case of brain tumors, where the choice between an exhaustive curative treatment and the risk of relapse for a patient with an unstable mental condition may jeopardize the long-term treatment success and quality of life.
Brain-infiltrating lymphocytes have been shown to be predictive of improved survival in patients with GBM. Clinical studies examining the immunotherapy of patients with brain tumor infiltrating immune cells have the prospect of improving patients' outcome.
Many new discoveries have been made with regard to brain cancer over the past few years. These include advances to improve diagnosis, prognosis, and treatments for metastatic tumors.
In the United States, the rate of brain cancer is about 4 per million every year and is most prevalent in adults and children aged 40–50 years. The age-specific risk for brain cancer in the U.S. has a downward trend from the highest rate in children aged 0–18 years in 1975 to a gradual decline of about 15%/year from 1983 to 2008. Although, the relative risk of brain cancer is lower in Finland than in the U.S, there are still about 3–4 brain cancer cases per 100,000 in Finland every year and about 1 in 75 people with brain cancer are Finnish citizens or have Finnish ancestors. Finland's low prevalence of brain cancer relative to the U.S.
While mRSI has been used successfully in oncologic as well as non oncologic uses, it has proven to be one of the most sophisticated modalities for treatment planning and is not typically used in patients for whom MRI has not already been obtained.
There are no studies specifically investigating the possibility that MRSI might provide information relevant for tumour grading or treatment response. However, MRSI has been used for research purposes that in turn may provide useful information. In particular, MRSI of gliomas can be used to assess metabolic changes after the initiation of treatment. The use of MRSI to evaluate treatment response after other interventions (e.g. the administration of some chemotherapeutic agents) has not yet been investigated.